Casopitant
Clinical data | |
---|---|
Other names | (2R,4S)-4-(4-Acetylpiperazin-1-yl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C30H35F7N4O2 |
Molar mass | 616.625 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Casopitant (INN,[1]: 208 tentative trade names Rezonic (U.S.), Zunrisa (Europe)) is a neurokinin 1 receptor (NK1R) antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[2] It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[3]
See also
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List56" (PDF). World Health Organization. 2006. Retrieved 17 November 2016.
- ↑ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer Journal. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612. S2CID 43224257.
- ↑ "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Archived from the original (PDF) on 15 October 2009. Retrieved 21 December 2009.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.